PDUFA VI: Breakthrough Issues Among US FDA Priorities
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has placed the breakthrough therapy program on its agenda for potential changes as part of the upcoming prescription drug user fee agreement, PDUFA VI.